J CORRAL MEDICAL ONCOLOGY SL
Company details
- No Activa NIF/CIF: B90142167
-
-
-
-
Address: Calle Almirante Lobo, 2, 41001 Sevilla, Sevilla, España See in map
-
-
Featured products:
More information on J CORRAL MEDICAL ONCOLOGY SL
-
12/06/2018 | BORME act no.: 247465 | Register: SEVILLACeses/Dimisiones
-
12/06/2018 | BORME act no.: 247465 | Register: SEVILLANombramientos
-
12/06/2018 | BORME act no.: 247465 | Register: SEVILLAOtros conceptos
-
12/06/2018 | BORME act no.: 247465 | Register: SEVILLADisolución
-
16/07/2014 | BORME act no.: 294527 | Register: SEVILLAConstitución
-
16/07/2014 | BORME act no.: 294527 | Register: SEVILLANombramientos
Other information
The CIF assigned to J CORRAL MEDICAL ONCOLOGY SL is B90142167, while its current business status is dissolved. The company operates in the economic sector identified by the CNAE 412 - Construcción de edificios. In addition, its activity corresponds to the SIC classification 6552 - Urbanizadoras y promotoras.
The template of J CORRAL MEDICAL ONCOLOGY SL includes Between 1 and 9 employees, and the company reports an annual turnover of less than 2 million euros. J CORRAL MEDICAL ONCOLOGY SL is registered in the Mercantile Registry of Sevilla and accumulates a total of 3 registration charges. The most recent announcement in Borme was published on 12/06/2018, while its last deposit of ordinary annual accounts is related to the - exercise.
If you want to obtain contact information for J CORRAL MEDICAL ONCOLOGY SL, such as the telephone number, postal address, or website, you can consult our Company Data module.
To access more details about J CORRAL MEDICAL ONCOLOGY SL, consider reviewing one of our available financial reports, the company's Annual Accounts, or verifying its outstanding payments registered in the RAI delinquency file.
The financial, commercial, and legal information provided about J CORRAL MEDICAL ONCOLOGY SL comes from official data sources and is automatically updated every day.
Do you want to know more about J CORRAL MEDICAL ONCOLOGY SL??
Find out more about this company by consulting these reports: